- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Daou woos Perot Systems in hopes of potential buyout
Daou woos Perot Systems in hopes of potential buyoutHealthcare information systems company and application service provider Daou Systems is hoping to join forces with Perot Systems and is currently negotiating a potential buyout. According to
Daou woos Perot Systems in hopes of potential buyout
Healthcare information systems company and application service provider Daou Systems is hoping to join forces with Perot Systems and is currently negotiating a potential buyout. According to the San Diego, CA-based firm, the purchase price being discussed is not a premium over its market price. Despite the ongoing talks, Daous stock price dropped over 20% to $2.19/share on August 11 from a closing price of $2.75/share on August 9, following the companys poor second quarter earnings report.
Daou reported a net loss of $2.8 million, or 16¢ per share, on revenue of $16.1 million for second quarter 2000, compared to net income of $60,000 on revenue of $27 million for second quarter 1999. The company blames its lower-than-expected earnings on lagging demand for healthcare IT services due to continued effects of Y2K and the Balanced Budget Act, managed-care cost pressures, slow demand for HIPAA-related services, and uncertainties surrounding healthcare integration.
In related news, Perot Systems has closed a strategic agreement to provide infrastructure design and implementation and operational support systems to Tellaire, a telecommunications provider of laser-based broadband communications. This partnership will further the Dallas firms reach in wireless broadband.
- Search Again
- Return To HNN Homepage
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
